公开(公告)号：EP1516542A1

公开(公告)日：2005-03-23

申请号：EP04025722.2

申请日：2002-03-19

申请人： BAUSCH & LOMB INCORPORATED ,  GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS ,  Wyeth

发明人： Ferris, Frederick, L, III ,  Bartels, Stephen Paul ,  Baustian, Cara Larraine ,  Souerwine, David A. ,  Bunce, George Edwin ,  Ellenbogen, Leon ,  Kinoshita, Jin ,  Smith, James Cecil, Jr.

IPC分类号： A23L1/303 ,  A23L1/304 ,  A61K31/375 ,  A61K31/355 ,  A61K31/07 ,  A61K33/30 ,  A61K33/34

CPC分类号： A61K33/34 ,  A23L5/44 ,  A23L33/105 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23V2002/00 ,  A61K31/07 ,  A61K31/355 ,  A61K31/375 ,  A61K33/30 ,  A61K2300/00 ,  A23V2250/708 ,  A23V2250/712 ,  A23V2250/211 ,  A23V2250/1642 ,  A23V2250/1588 ,  A23V2250/2104 ,  A23V2250/2132 ,  A23V2250/702

摘要： A nutritional or dietary supplement composition that strengthens and promotes retinal health through the prevention, stabilization, reversal and/or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The nutritional or dietary supplement composition may likewise reduce the risk of vision loss associated with the development of cataracts. The essential ingredients of the nutritional or dietary supplement composition are vitamin C, vitamin E, beta-carotene, zinc and copper. The essential ingredients are preferably provided in a tablet form suitable for oral ingestion. Preferably the composition is taken in the form of one or two tablets taken twice daily.

摘要翻译： 营养或膳食补充剂组合物，通过降低发生晚期或晚期年龄相关性黄斑变性的晚期黄斑变性的风险，通过预防，稳定，逆转和/或治疗视力丧失来增强和促进视网膜健康 退化。 营养或膳食补充剂组合物同样可以降低与白内障发展相关的视力丧失的风险。 营养或膳食补充剂组合物的基本成分是维生素C，维生素E，β-胡萝卜素，锌和铜。 必需成分优选以适于口服摄取的片剂形式提供。 优选地，组合物以每天两次服用一片或两片片剂的形式摄取。

公开(公告)号：EP1383399A1

公开(公告)日：2004-01-28

申请号：EP02728516.2

申请日：2002-03-19

申请人： BAUSCH & LOMB INCORPORATED ,  GOVERNMENT OF THE UNITED STATES OF AMERICA,as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS ,  Wyeth

发明人： BARTELS, Stephen, Paul ,  BAUSTIAN, Cara, Larraine ,  SOUERWINE, David, A. ,  BUNCE, George, Edwin ,  ELLENBOGEN, Leon ,  FERRIS, Federick, L., III ,  KINOSHITA, Jin ,  SMITH, James, Cecil, Jr.

IPC分类号： A23L1/303 ,  A23L1/304 ,  A61K31/375 ,  A61K31/355 ,  A61K31/07 ,  A61K33/30 ,  A61K33/34

CPC分类号： A61K33/34 ,  A23L5/44 ,  A23L33/105 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23V2002/00 ,  A61K31/07 ,  A61K31/355 ,  A61K31/375 ,  A61K33/30 ,  A61K2300/00 ,  A23V2250/708 ,  A23V2250/712 ,  A23V2250/211 ,  A23V2250/1642 ,  A23V2250/1588 ,  A23V2250/2104 ,  A23V2250/2132 ,  A23V2250/702

摘要： A nutritional or dietary supplement composition that strengthens and promotes retinal health through the prevention, stabilization, reversal and/or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The nutritional or dietary supplement composition may likewise reduce the risk of vision loss associated with the development of cataracts. The essential ingredients of the nutritional or dietary supplement composition are vitamin C, vitamin E, beta-carotene, zinc and copper. The essential ingredients are preferably provided in a tablet form suitable for oral ingestion. Preferably the composition is taken in the form of one or two tablets taken twice daily.

公开(公告)号：EP1697399B1

公开(公告)日：2016-11-23

申请号：EP04814140.2

申请日：2004-12-10

申请人： GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS

发明人： SCHLOM, Jeffrey ,  TSANG, Kwong-Yok

IPC分类号： G01N33/53 ,  G01N33/567 ,  C07K16/18 ,  C07K7/64

CPC分类号： A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/4727 ,  C07K14/70596 ,  C12N15/85

摘要： Novel MUC-1 epitopes outside the VNTR region are identified. In addition, the first agonist epitope of MUC-1 is described. The employment of agonist epitopes in peptide, protein and vector-based vaccine may well aid in the development of effective vaccines for a range of human cancers.

公开(公告)号：EP0623169B1

公开(公告)日：2003-04-02

申请号：EP93911555.6

申请日：1993-01-15

申请人： GENELABS TECHNOLOGIES, INC. ,  GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS

发明人： REYES, Gregory R. ,  BRADLEY, Daniel W. ,  TWU, Jr-Shin ,  PURDY, Michael A. ,  TAM, Albert W. ,  KRAWCZYNSKI, Krzysztof Z. ,  YARBOUGH, Patrice O.

IPC分类号： C12N15/51 ,  A61K39/29

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C07K16/10 ,  C07K2319/00 ,  C07K2319/23 ,  C07K2319/40 ,  C07K2319/61 ,  C12N2770/28022 ,  C12N2770/28122 ,  G01N33/5767

摘要： Antigen and antibody vaccine compositions effective in preventing hepatitis E virus (HEV) infection are disclosed. The antigen composition includes a peptide corresponding to a carboxyl terminal end region of the capsid protein encoded by the second open reading frame (2) of the HEV genome. The composition is effective in preventing HEV infection after vaccination. The antibody composition contains an antibody effective to block HEV infection of human primary hepatocytes in culture.

公开(公告)号：EP1516542B1

公开(公告)日：2009-04-22

申请号：EP04025722.2

申请日：2002-03-19

申请人： BAUSCH & LOMB INCORPORATED ,  GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS ,  Wyeth

发明人： Ferris, Frederick, L, III ,  Bartels, Stephen Paul ,  Baustian, Cara Larraine ,  Souerwine, David A. ,  Bunce, George Edwin ,  Ellenbogen, Leon ,  Kinoshita, Jin ,  Smith, James Cecil, Jr.

IPC分类号： A23L1/303 ,  A23L1/304 ,  A61K31/375 ,  A61K31/355 ,  A61K31/07 ,  A61K33/30 ,  A61K33/34

CPC分类号： A61K33/34 ,  A23L5/44 ,  A23L33/105 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23V2002/00 ,  A61K31/07 ,  A61K31/355 ,  A61K31/375 ,  A61K33/30 ,  A61K2300/00 ,  A23V2250/708 ,  A23V2250/712 ,  A23V2250/211 ,  A23V2250/1642 ,  A23V2250/1588 ,  A23V2250/2104 ,  A23V2250/2132 ,  A23V2250/702

公开(公告)号：EP0476130B1

公开(公告)日：2008-07-09

申请号：EP91908163.8

申请日：1991-04-05

申请人： GENELABS TECHNOLOGIES, INC. ,  GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS

发明人： REYES, Gregory, R. ,  YARBOUGH, Patrice, O. ,  BRADLEY, Daniel, W. ,  KRAWCZYNSKI, Krzysztof, Z. ,  TAM, Albert ,  FRY, Kirk, E.

IPC分类号： C12N15/51 ,  C07K14/08 ,  G01N33/576 ,  C12Q1/70 ,  A61K39/29 ,  C12N7/02

CPC分类号： C07K16/10 ,  A61K38/00 ,  A61K39/00 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/61 ,  C12N2770/24222

公开(公告)号：EP0696205B1

公开(公告)日：2002-01-23

申请号：EP94912975.3

申请日：1994-04-11

申请人： GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS

发明人： MAJOR, Eugene O. ,  TORNATORE, Carlo S. ,  BANKIEWICZ, Kris

IPC分类号： A61K48/00 ,  A61K35/54

CPC分类号： C12N9/0071 ,  A61K35/30 ,  A61K35/54 ,  A61K38/00 ,  A61K48/00 ,  A61K2035/126 ,  C12N5/0622 ,  C12N15/85 ,  C12N2510/04 ,  C12Y114/13041 ,  C12Y114/16002 ,  Y10S435/948

摘要： Human fetal neuro-derived cell lines are implanted into host tissues. The methods allow for treatment of a variety of neurological disorders and other diseases. A preferred cell line is SVG.

公开(公告)号：EP0666751B1

公开(公告)日：2001-09-12

申请号：EP93921524.0

申请日：1993-09-17

申请人： SMITHKLINE BEECHAM BIOLOGICALS S.A. ,  GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS

发明人： FUNKHOUSER, Ann W. ,  EMERSON, Suzanne U. ,  PURCELL, Robert H. ,  D'HONDT, Eric

IPC分类号： C12N15/51 ,  C12N7/00 ,  C12N7/04 ,  A61K39/29

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/545 ,  C12N7/00 ,  C12N2770/32421 ,  C12N2770/32422 ,  C12N2770/32432 ,  C12N2770/32434 ,  Y02A50/464

摘要： A live hepatitis A virus adapted to growth in MRC-5 cells, which HAV is preferably characterized by suitable attenuation for effective vaccine administration to humans and animals without inactivation, methods for adapting HAV to growth in MRC-5, vaccine compositions and method of vaccinating humans against HAV infection.

公开(公告)号：EP1697399A2

公开(公告)日：2006-09-06

申请号：EP04814140.2

申请日：2004-12-10

申请人： GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS

发明人： SCHLOM, Jeffrey ,  TSANG, Kwong-Yok

IPC分类号： C07K1/00

CPC分类号： A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/4727 ,  C07K14/70596 ,  C12N15/85

摘要： Novel MUC-1 epitopes outside the VNTR region are identified. In addition, the first agonist epitope of MUC-1 is described. The employment of agonist epitopes in peptide, protein and vector-based vaccine may well aid in the development of effective vaccines for a range of human cancers.

公开(公告)号：EP1383399B1

公开(公告)日：2004-11-03

申请号：EP02728516.2

申请日：2002-03-19

申请人： BAUSCH & LOMB INCORPORATED ,  GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS ,  Wyeth

发明人： BARTELS, Stephen, Paul ,  BAUSTIAN, Cara, Larraine ,  SOUERWINE, David, A. ,  BUNCE, George, Edwin ,  ELLENBOGEN, Leon ,  FERRIS, Federick, L., III ,  KINOSHITA, Jin ,  SMITH, James, Cecil, Jr.

IPC分类号： A23L1/303 ,  A23L1/304 ,  A61K31/375 ,  A61K31/355 ,  A61K31/07 ,  A61K33/30 ,  A61K33/34

CPC分类号： A61K33/34 ,  A23L5/44 ,  A23L33/105 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23V2002/00 ,  A61K31/07 ,  A61K31/355 ,  A61K31/375 ,  A61K33/30 ,  A61K2300/00 ,  A23V2250/708 ,  A23V2250/712 ,  A23V2250/211 ,  A23V2250/1642 ,  A23V2250/1588 ,  A23V2250/2104 ,  A23V2250/2132 ,  A23V2250/702

摘要： A nutritional or dietary supplement composition that strengthens and promotes retinal health through the prevention, stabilization, reversal and/or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The nutritional or dietary supplement composition may likewise reduce the risk of vision loss associated with the development of cataracts. The essential ingredients of the nutritional or dietary supplement composition are vitamin C, vitamin E, beta-carotene, zinc and copper. The essential ingredients are preferably provided in a tablet form suitable for oral ingestion. Preferably the composition is taken in the form of one or two tablets taken twice daily.

摘要翻译： 一种营养或膳食补充剂组合物，其通过降低患早期年龄相关性黄斑病的患晚期或高龄相关性黄斑变性的风险，通过预防，稳定，逆转和/或治疗视力丧失来增强和促进视网膜健康 退化。 营养或膳食补充剂组合物同样可以降低与白内障发展相关的视力丧失的风险。 营养或膳食补充剂组合物的基本成分是维生素C，维生素E，β-胡萝卜素，锌和铜。 基本成分优选以适于口服摄入的片剂形式提供。 优选地，组合物以每日两次服用一次或两次片剂的形式服用。